Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 875 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0 mg placebo Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ramipril for the Treatment of Oligospermia

NCT01856361
View directory record Official record
Conditions
Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548987
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Anniston, Alabama • Fresno, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Single Dose PK

NCT00444028
View directory record Official record
Conditions
Schizophrenia
Interventions
inhaled Loxapine 0.625 mg, inhaled Loxapine 1.25 mg, inhaled Loxapine 2.5 mg, inhaled Loxapine 5 mg, inhaled Loxapine 10 mg, inhaled Placebo (0 mg)
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

NCT01452607
View directory record Official record
Conditions
Hearing Loss, Cancer
Interventions
SPI-1005, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
19 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

NCT00708201
View directory record Official record
Conditions
Postoperative Ileus
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Laguna Hills, California • Aurora, Colorado • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT04673357
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

NCT00277212
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lamotrigine + Aripiprazole, Lamotrigine + Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

NCT02394028
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional

Asenapine for Bipolar Depression

NCT01807741
View directory record Official record
Conditions
Bipolar Depression
Interventions
Asenapine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

NCT03347188
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

NCT00283816
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

NCT00119678
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

NCT01404585
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, BMS-817399
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Palm Desert, California • Sarasota, Florida • Middleburg Heights, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Epicatechin-rich Cocoa on Collagen Synthesis

NCT03214133
View directory record Official record
Conditions
Collagen Synthesis
Interventions
Epicatechin-rich cocoa dose response, Epicatechin-rich cocoa vs placebo on performance
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Contact: Developing New Clinical Management Strategies

NCT03812588
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

NCT00819390
View directory record Official record
Conditions
HIV Infections
Interventions
Chloroquine, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine

NCT05811923
View directory record Official record
Conditions
Metabolic Syndrome, Caffeine
Interventions
Venous Blood Collection, Resting Metabolic Rate Determination, Mood State, Visual Analog Scales
Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 30, 2026, 5:13 AM EDT
Active, not recruiting Phase 4 Interventional

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

NCT05285891
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Placebo for Ocrelizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
13
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

NCT00960362
View directory record Official record
Conditions
Inflammation, Systemic Lupus Erythematosus (SLE)
Interventions
AGS-009, placebo
Drug
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Kansas City, Kansas • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 30, 2026, 5:13 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

NCT05997641
View directory record Official record
Conditions
Healthy, Safety and Tolerability
Interventions
DF-003, Placebo
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

B Cell Induction in Pediatric Lung Transplantation

NCT02266888
View directory record Official record
Conditions
Lung Transplant
Interventions
Rituximab (Rituxan®), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of an Extract of Naringenin

NCT03582553
View directory record Official record
Conditions
Safety Issues, Pharmacokinetics
Interventions
Naringenin, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Sep 30, 2026, 5:13 AM EDT